AAA Screening in Men Over 65 Reduces Mortality

screening abdominal aortic aneurysmSystematic screening for abdominal aortic aneurysm (AAA) targeting all men over 65 years old (not just those presenting risk factors) was associated with a drop in the mortality rate specific for this disease, according to the Swedish Nationwide Screening Program.

 

While 667 men were examined for AAA, the number of patients who required treatment to prevent premature death due to aneurysm rupture was merely 1.5.

 

Such amazing treatment efficacy justifies screening despite the relatively low prevalence of this disease.

 

Randomized studies showed that screening through ultrasound followed by preventive surgery can reduce associated mortality in selected populations, but such a selection differs by location. This is, precisely, the novelty in this study: no selection was made; all men over 65 years old were studied.

 

In this registry, of 302,957 men who received an invitation to be screened, 84% finally accepted, a very high percentage.

 

AAA was detected in 1.5% of men, 29% of which underwent preventive surgery over a mean follow-up of 4.5 years.

 

Mortality at 30 days was significantly lower for endovascular treatment compared to open surgery.

 

Endovascular treatment: 0.3%

Open surgery:  1.3%

(p <0.001)

 

There was a significant reduction in mortality (4%) per year of screening (p = 0.02).

 

From 2000 (before the introduction of screening) to 2014, associated mortality dropped from 74 to 45 patients every 100,000 subjects.

 

Conclusion

Systematic screening for abdominal aortic aneurysm in men over 65 years old is highly cost-effective and reduces mortality associated to aneurysm rupture.

 

Original title: Outcome of the Swedish nationwide abdominal aortic aneurysm screening program.

Reference: Wanhainen A et al. Circulation 2016; Epub ahead of print.

 

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....